Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Expert Opinion on Therapeutic Targets|June 13, 2012
Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignanciesAlberto M Martelli, Francesca Chiarini, Camilla Evangelisti, et al.Advances in Biological Regulation|May 14, 2014
Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cellsAlberto M Martelli, Annalisa Lonetti, Francesca Buontempo, et al.International Journal of Oncology|June 28, 2014
Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review)Camilla Evangelisti, Cecilia Evangelisti, Francesca Chiarini, et al.Expert Opinion on Therapeutic Targets|June 13, 2013
Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemiaCamilla Evangelisti, Cecilia Evangelisti, Daniela Bressanin, et al.Cell Cycle (Georgetown, Tex.)|June 21, 2012
Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3aFrancesca Buontempo, Francesca Chiarini, Daniela Bressanin, et al.Oncotarget|August 14, 2012
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levelsDaniela Bressanin, Camilla Evangelisti, Francesca Ricci, et al.Cell Cycle (Georgetown, Tex.)|May 31, 2014
Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemiaAntonino Maria Spartà, Daniela Bressanin, Francesca Chiarini, et al.Oncotarget|December 17, 2013
MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemiaAnnalisa Astolfi, Francesca Vendemini, Milena Urbini, et al.Oncotarget|December 29, 2012
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemiaFrancesca Chiarini, Annalisa Lonetti, Gabriella Teti, et al.Pageof 2